M. Kawakami et al., VIDARABINE THERAPY FOR VIRUS-ASSOCIATED CYSTITIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 20(6), 1997, pp. 485-490
We describe a method of diagnosing virus-associated cystitis after all
ogeneic bone marrow transplantation (BMT) and treatment with vidarabin
e therapy, At 7-10 days post-BMT when cystitis was suspected, we obser
ved urinary sediments by the Papanicolaou stain to detect virus inclus
ion bodies. When positive, we examined urinary sediments by transmissi
on electron microscope and measured the diameter of viral particles to
determine the families, This process needed only 4 days, Among 16 con
secutive cases, adenovirus and polyomavirus were each detected in thre
e. Adenovirus caused hemorrhagic cystitis in two eases and cystitis wi
thout macroscopic hematuria in one case, Polyomavirus caused cystitis
without macroscopic hematuria in one case, Polyomavirus was also detec
ted in two cases without any symptoms, Vidarabine (10 mg/kg/day i.v.)
was administered for 5 days as one course, Soon after one course of vi
darabine, most symptoms subsided and virus inclusion bodies disappeare
d in all cases except for one with severe hemorrhagic cystitis. From t
hese experiences, vidarabine reduces excretion of adenovirus and polyo
mavirus in the urine of BMT recipients and improves clinical symptoms
in some cases of cystitis associated with these viruses.